Ad hoc afatinib in an eldery lung cancer patient with EGFR exon 19 deletion L747-A750>P

Adv Respir Med. 2022;90(3):234-235. doi: 10.5603/ARM.a2022.0034.
No abstract available

Keywords: biomarkers; molecular targets; non-small cell lung carcinoma (NSCLC); personalized therapy; targeted agents.

MeSH terms

  • Afatinib / therapeutic use
  • ErbB Receptors / genetics
  • Exons / genetics
  • Humans
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics

Substances

  • Afatinib
  • EGFR protein, human
  • ErbB Receptors